Form 4: Nurix CFO Granted Significant Equity Awards

Nurix Therapeutics' Chief Financial Officer, Hans van Houte, received significant equity awards, including stock options and restricted stock units, as part of his compensation.

Summary

• Hans van Houte, Chief Financial Officer of Nurix Therapeutics, Inc. (NRIX), was granted derivative securities on February 10, 2026.
• The awards include 93,750 employee stock options with an exercise price of $16.45 per share.
• The stock options vest monthly at a rate of 1/36 of the total shares, beginning March 10, 2026, and will be fully vested by February 9, 2029.
• The stock options have an expiration date of February 9, 2036.
• Additionally, 42,875 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of common stock.
• The RSUs will vest quarterly at a rate of 1/12 of the total award over three years, with the first quarterly increment vesting on July 30, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at aligning management incentives with long-term company performance and shareholder interests.

Positives

• The grant of equity awards aligns the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining key executives in the biotechnology sector.

Future Outlook

The filing does not contain forward-looking statements or guidance beyond the vesting and expiration schedules of the granted equity awards.

Industry Context

StockSavvy.ai notes that the grant of stock options and restricted stock units to key executives is a common and established practice within the biotechnology and pharmaceutical industries to attract, retain, and incentivize talent, aligning their performance with shareholder value creation.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options and vesting of RSUs, but also benefit from aligned executive incentives.
• Employees: Retention of a key executive (CFO) is generally positive for organizational stability and strategic execution.

Next Steps

• Continued provision of service by the Reporting Person to the Issuer for vesting of both stock options and RSUs.
• Monthly vesting of stock options beginning March 10, 2026, until fully vested on February 9, 2029.
• Quarterly vesting of RSUs beginning July 30, 2026, over three years.

Key Dates

Keywords

Nurix Therapeutics, NRIX, Form 4, Insider Transaction, Equity Compensation, Stock Option, Restricted Stock Units, CFO, Executive Compensation